JP2010524849A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010524849A5 JP2010524849A5 JP2010501126A JP2010501126A JP2010524849A5 JP 2010524849 A5 JP2010524849 A5 JP 2010524849A5 JP 2010501126 A JP2010501126 A JP 2010501126A JP 2010501126 A JP2010501126 A JP 2010501126A JP 2010524849 A5 JP2010524849 A5 JP 2010524849A5
- Authority
- JP
- Japan
- Prior art keywords
- rap
- cyclic
- mutation
- peptide
- rap peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010071471 glutamyl-leucyl-lysyl-valyl-leucyl-methionyl-glutamyl-lysyl-glutamyl-leucine Proteins 0.000 claims description 87
- 125000004122 cyclic group Chemical group 0.000 claims description 86
- 230000035772 mutation Effects 0.000 claims description 54
- 150000001413 amino acids Chemical class 0.000 claims description 30
- 239000003814 drug Substances 0.000 claims description 12
- 229940124597 therapeutic agent Drugs 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 239000000032 diagnostic agent Substances 0.000 claims description 10
- 229940039227 diagnostic agent Drugs 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 230000002378 acidificating effect Effects 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 239000013543 active substance Substances 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 239000003102 growth factor Substances 0.000 claims description 6
- 230000007514 neuronal growth Effects 0.000 claims description 6
- 208000012902 Nervous system disease Diseases 0.000 claims description 4
- 208000025966 Neurological disease Diseases 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 108010091175 Matriptase Proteins 0.000 claims description 3
- 102100037942 Suppressor of tumorigenicity 14 protein Human genes 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 101800001224 Disintegrin Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 101001043594 Homo sapiens Low-density lipoprotein receptor-related protein 5 Proteins 0.000 claims description 2
- 101000896414 Homo sapiens Nuclear nucleic acid-binding protein C1D Proteins 0.000 claims description 2
- 101001043564 Homo sapiens Prolow-density lipoprotein receptor-related protein 1 Proteins 0.000 claims description 2
- 101000666934 Homo sapiens Very low-density lipoprotein receptor Proteins 0.000 claims description 2
- 102100021926 Low-density lipoprotein receptor-related protein 5 Human genes 0.000 claims description 2
- 102000005741 Metalloproteases Human genes 0.000 claims description 2
- 108010006035 Metalloproteases Proteins 0.000 claims description 2
- 108010006519 Molecular Chaperones Proteins 0.000 claims description 2
- 102000005431 Molecular Chaperones Human genes 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 claims description 2
- 102100039066 Very low-density lipoprotein receptor Human genes 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 230000001363 autoimmune Effects 0.000 claims description 2
- 230000008499 blood brain barrier function Effects 0.000 claims description 2
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 210000003169 central nervous system Anatomy 0.000 claims description 2
- 201000007455 central nervous system cancer Diseases 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002132 lysosomal effect Effects 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 210000004498 neuroglial cell Anatomy 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 230000007310 pathophysiology Effects 0.000 claims description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000000861 pro-apoptotic effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91923807P | 2007-03-21 | 2007-03-21 | |
| PCT/US2008/057863 WO2008116171A1 (en) | 2007-03-21 | 2008-03-21 | Cyclic receptor-associated protein (rap) peptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010524849A JP2010524849A (ja) | 2010-07-22 |
| JP2010524849A5 true JP2010524849A5 (enExample) | 2012-04-19 |
Family
ID=39591450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010501126A Pending JP2010524849A (ja) | 2007-03-21 | 2008-03-21 | 環状受容体関連蛋白ペプチド |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8440629B2 (enExample) |
| EP (1) | EP2132224B1 (enExample) |
| JP (1) | JP2010524849A (enExample) |
| KR (2) | KR101801454B1 (enExample) |
| CN (1) | CN101861334A (enExample) |
| AT (1) | ATE539089T1 (enExample) |
| BR (1) | BRPI0809234A2 (enExample) |
| CA (1) | CA2681522A1 (enExample) |
| MX (1) | MX2009010148A (enExample) |
| WO (1) | WO2008116171A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004060403A2 (en) | 2003-01-06 | 2004-07-22 | Angiochem Inc. | Aprotinin and anglos as carriers across the blood-brain barrier |
| US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| CA2721019C (en) | 2008-04-18 | 2015-09-15 | Angiochem Inc. | Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use |
| US8129341B2 (en) * | 2008-08-25 | 2012-03-06 | New York University | Methods for treating diabetic wounds |
| MX2011004017A (es) | 2008-10-15 | 2011-06-24 | Angiochem Inc | Conjugados de agonistas glp-1 y usos de los mismos. |
| WO2010043049A1 (en) | 2008-10-15 | 2010-04-22 | Angiochem Inc. | Etoposide and doxorubicin conjugates for drug delivery |
| US9914754B2 (en) | 2008-12-05 | 2018-03-13 | Angiochem Inc. | Conjugates of neurotensin or neurotensin analogs and uses thereof |
| CA2747220A1 (en) | 2008-12-17 | 2010-06-24 | Richard Beliveau | Membrane type-1 matrix metalloprotein inhibitors and uses thereof |
| WO2010117957A2 (en) * | 2009-04-06 | 2010-10-14 | Mayo Foundation For Medical Education And Research | Methods and materials for delivering molecules |
| CN102510759A (zh) | 2009-04-20 | 2012-06-20 | 安吉奥开米公司 | 利用与血管肽-2类似物结合的抗癌剂治疗卵巢癌 |
| WO2011000095A1 (en) | 2009-07-02 | 2011-01-06 | Angiochem Inc. | Multimeric peptide conjugates and uses thereof |
| CN102905716B (zh) * | 2010-01-28 | 2016-06-01 | 雷普特制药公司 | 以受体相关蛋白(rap)肽-岩藻糖苷酶抑制剂偶联物治疗肝病症的方法 |
| CA2805412C (en) | 2010-06-17 | 2021-04-27 | New York University | Therapeutic and cosmetic uses and applications of calreticulin |
| US8956859B1 (en) | 2010-08-13 | 2015-02-17 | Aviex Technologies Llc | Compositions and methods for determining successful immunization by one or more vaccines |
| GB201220474D0 (en) * | 2012-11-14 | 2012-12-26 | Sagetis Biotech Sl | Polypeptides |
| EP3038657A2 (en) | 2013-08-28 | 2016-07-06 | Bioasis Technologies Inc. | Cns-targeted conjugates having modified fc regions and methods of use thereof |
| EP3259280A4 (en) * | 2015-02-20 | 2018-07-18 | The Regents of The University of California | Methods and compositions for treating glaucoma |
| WO2016205367A1 (en) | 2015-06-15 | 2016-12-22 | Angiochem Inc. | Methods for the treatment of leptomeningeal carcinomatosis |
| CN109422801B (zh) * | 2017-08-31 | 2022-07-08 | 复旦大学 | 多功能靶向多肽rap及其在制备肿瘤靶向递送系统中的用途 |
| JP2021504492A (ja) * | 2017-11-29 | 2021-02-15 | ボード オブ リージェンツ オブ ザ ユニバーシティ オブ テキサス システム | 癌治療のための組成物および方法 |
| US12305171B2 (en) | 2018-12-27 | 2025-05-20 | Bioaffinity Technologies, Inc. | Compositions and methods for treating cancer |
| CN113508175B (zh) * | 2018-12-27 | 2025-08-19 | 生物阿非尼提科技公司 | 用于治疗癌症的组合物和方法 |
| US11572394B2 (en) * | 2020-02-16 | 2023-02-07 | Pasteur Institute Of Iran | Peptides for targeting LRP6-overexpressed cells |
| EP3954393A1 (en) | 2020-08-13 | 2022-02-16 | Bioasis Technologies Inc. | Combination therapies for delivery across the blood brain barrier |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4394448A (en) | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
| IT1122765B (it) * | 1978-11-06 | 1986-04-23 | Srm Hydromekanik Ab | Frizione a dischi multipli |
| US4391904A (en) | 1979-12-26 | 1983-07-05 | Syva Company | Test strip kits in immunoassays and compositions therein |
| US5186941A (en) | 1983-05-06 | 1993-02-16 | Vestar, Inc. | Vesicle formulation for the controlled release of therapeutic agents |
| US6048729A (en) | 1987-05-01 | 2000-04-11 | Transkaryotic Therapies, Inc. | In vivo protein production and delivery system for gene therapy |
| US6063630A (en) | 1991-11-05 | 2000-05-16 | Transkaryotic Therapies, Inc. | Targeted introduction of DNA into primary or secondary cells and their use for gene therapy |
| US6238908B1 (en) | 1995-06-07 | 2001-05-29 | Aastrom Biosciences, Inc. | Apparatus and method for maintaining and growth biological cells |
| ATE293883T1 (de) | 1996-01-16 | 2005-05-15 | Ronald J Sokol | Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen |
| TW492882B (en) | 1997-11-28 | 2002-07-01 | Caleb Pharmaceuticals Inc | Cholinergic antagonist plaster composition |
| US6585971B1 (en) | 1999-11-12 | 2003-07-01 | Harbor-Ucla Research And Education Institute | Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating disease caused by deficiencies thereof |
| US6569661B1 (en) | 1999-11-12 | 2003-05-27 | Biomarin Pharmaceutical Inc. | Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof |
| US6426208B1 (en) | 1999-11-12 | 2002-07-30 | Harbor-Ucla Research And Education Institute | Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof |
| US6261595B1 (en) | 2000-02-29 | 2001-07-17 | Zars, Inc. | Transdermal drug patch with attached pocket for controlled heating device |
| US6596762B2 (en) | 2001-05-17 | 2003-07-22 | The Regents Of The University Of Colorado | Antioxidant compositions and use for treatment of hepatic steatosis and steatohepatitis |
| US7485314B2 (en) | 2002-05-06 | 2009-02-03 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Induction of antigen specific immunologic tolerance |
| WO2005002515A2 (en) * | 2003-06-20 | 2005-01-13 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| WO2006138343A2 (en) | 2005-06-14 | 2006-12-28 | Raptor Pharmaceutical Inc. | Compositions comprising receptor - associated protein (rap) variants specific for lrp2 and uses thereof |
| EP2063905B1 (en) | 2006-09-18 | 2014-07-30 | Raptor Pharmaceutical Inc | Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates |
-
2008
- 2008-03-21 KR KR1020157020697A patent/KR101801454B1/ko not_active Expired - Fee Related
- 2008-03-21 CA CA002681522A patent/CA2681522A1/en not_active Abandoned
- 2008-03-21 MX MX2009010148A patent/MX2009010148A/es active IP Right Grant
- 2008-03-21 CN CN200880016942A patent/CN101861334A/zh active Pending
- 2008-03-21 KR KR1020097022037A patent/KR20100015786A/ko not_active Ceased
- 2008-03-21 JP JP2010501126A patent/JP2010524849A/ja active Pending
- 2008-03-21 US US12/600,786 patent/US8440629B2/en not_active Expired - Fee Related
- 2008-03-21 BR BRPI0809234-6A patent/BRPI0809234A2/pt not_active Application Discontinuation
- 2008-03-21 AT AT08732675T patent/ATE539089T1/de active
- 2008-03-21 WO PCT/US2008/057863 patent/WO2008116171A1/en not_active Ceased
- 2008-03-21 EP EP08732675A patent/EP2132224B1/en not_active Not-in-force
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010524849A5 (enExample) | ||
| KR101617790B1 (ko) | 치료, 진단과 실험적 혼합물들의 운반을 위한 공학적으로 가변된 나노입자 및 치료용 관련 조성물 | |
| TWI886164B (zh) | 1價ccap生成物之製造方法 | |
| US20170007669A1 (en) | Peptide-mediated delivery of active agents across the blood-brain barrier | |
| JP2009502135A5 (enExample) | ||
| JP2013542913A5 (enExample) | ||
| IL321500A (en) | Pre-stabilized hmpv f proteins | |
| JP7678654B2 (ja) | 複合体及びその使用 | |
| JP2017529059A5 (enExample) | ||
| BRPI0620806A2 (pt) | peptìdeos úteis como peptìdeos de penetração de célula | |
| US12465646B2 (en) | Linkers | |
| JP2015057058A (ja) | 組織傷害の修復におけるストロマ細胞由来因子１のプロテアーゼ耐性変異体 | |
| JP2015509097A5 (enExample) | ||
| AU2021202789A1 (en) | Cancer immunotherapeutic | |
| US20150252081A1 (en) | Methods and compositions for controlling assembly of viral proteins | |
| CA3066077A1 (en) | Tau aggregation inhibitors | |
| JP7674031B2 (ja) | 細胞透過性ペプチド | |
| JP2022118184A (ja) | コンジュゲートされたｃ１エステラーゼインヒビター及びその使用 | |
| WO2018106273A1 (en) | Collagen targeting nanofibers and nanosheets | |
| JP2025166082A (ja) | 分子ガイドシステムペプチド及びその使用 | |
| US20180340020A1 (en) | Peptide-mediated delivery of immunoglobulins across the blood-brain barrier | |
| US20230399378A1 (en) | Peptide-based delivery of agents | |
| JP7766489B2 (ja) | 免疫調節特性を有するペプチド | |
| WO2024042466A1 (en) | Brain penetrating peptides and methods of use thereof | |
| JP2005508875A5 (enExample) |